Analysts Set TransMedics Group, Inc. (NASDAQ:TMDX) Price Target at $122.70

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven ratings firms that are presently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $122.70.

Several equities analysts recently commented on the stock. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Piper Sandler dropped their price target on TransMedics Group from $110.00 to $90.00 and set an "overweight" rating for the company in a research note on Wednesday, December 11th. JPMorgan Chase & Co. reissued a "neutral" rating and set a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Oppenheimer reaffirmed an "outperform" rating and issued a $125.00 target price on shares of TransMedics Group in a report on Tuesday, December 3rd. Finally, TD Cowen cut their price target on TransMedics Group from $175.00 to $120.00 and set a "buy" rating on the stock in a research note on Monday, November 18th.

Insider Activity

In related news, Director Edward M. Basile sold 6,750 shares of the firm's stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the sale, the director now owns 732 shares of the company's stock, valued at $61,158.60. This trade represents a 90.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Tamer I. Khayal sold 1,084 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.00% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. USA Financial Formulas bought a new position in TransMedics Group in the third quarter worth approximately $55,000. Quarry LP lifted its holdings in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company's stock worth $58,000 after purchasing an additional 312 shares in the last quarter. National Bank of Canada FI grew its position in TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company's stock valued at $65,000 after purchasing an additional 262 shares during the period. Farther Finance Advisors LLC increased its stake in TransMedics Group by 187.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company's stock valued at $76,000 after purchasing an additional 316 shares in the last quarter. Finally, Rakuten Securities Inc. bought a new stake in TransMedics Group during the 3rd quarter valued at $126,000. 99.67% of the stock is owned by institutional investors.

TransMedics Group Trading Down 1.4 %

Shares of TMDX opened at $57.20 on Friday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group has a 52-week low of $56.03 and a 52-week high of $177.37. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of 60.85 and a beta of 2.12. The business's fifty day moving average is $71.50 and its 200-day moving average is $118.10.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business's revenue was up 63.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.12) EPS. Equities analysts anticipate that TransMedics Group will post 1 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.